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Abstract. – OBJECTIVE: Endothelial dys-
function (ED) predisposes to venous thrombo-
sis (VT) and post-thrombotic syndrome (PTS), 
a long-term VT-related complication. Sulodex-
ide (SDX) is a highly purified glycosaminogly-
can with antithrombotic, pro-fibrinolytic and an-
ti-inflammatory activity used in the treatment 
of chronic venous disease (CVD), including pa-
tients with PTS. SDX has recently obtained clin-
ical evidence in the “extension therapy” after 
initial-standard anticoagulant treatment for the 
secondary prevention of recurrent deep vein 
thrombosis (DVT). Herein, we investigated how 
SDX counteracts ED.
MATERIALS AND METHODS: Human umbil-
ical vein endothelial cells (HUVEC) were used. 
Metabolic and non metabolic-induced ED was 
induced by treating with methylglyoxal (MGO) or 
irradiation (IR), respectively. Bafilomycin A1 was 
used to inhibit autophagy. The production of re-
active oxygen species (ROS), tetrazolium bro-
mide (MTT) assay for cell viability, terminal de-
oxynucleotidyl transferase-mediated dUTP nick 
end labeling (TUNEL) assay for cell apoptosis, 
Real-time PCR and Western blot analysis for 
gene and protein expression were used.
RESULTS: SDX protected HUVEC from MGO- 
or IR-induced apoptosis by counteracting the 
activation of the intrinsic and extrinsic caspase 
cascades. The cytoprotective effects of SDX re-
sulted from a reduction in a) ROS production, b) 
neo-synthesis and release of pro-inflammatory 
cytokines (TNFα, IL1, IL6, IL8), c) DNA damage 
induced by MGO or IR. These effects were re-
duced when autophagy was inhibited.
CONCLUSIONS: Data herein collected indi-
cate the ability of SDX to counteract ED in-
duced by metabolic or non-metabolic stresses 
by involving the intracellular autophagy path-
way. Our experience significantly increases the 
knowledge of the mechanisms of action of SDX 
against ED and supports the use of SDX in the 
treatment of CVD, PTS and in the secondary pre-
vention of recurrent DVT.
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Introduction
Venous thrombosis (VT) is the most frequent, 
significantly mortal and morbid vascular dis-
ease1 that contributes to a substantial economic 
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burden2. Endothelial dysfunction (ED) has been 
shown to be the common denominator for the 
onset and recurrence of VT, and persistent ED 
has been shown to promote the post-thrombotic 
syndrome (PTS), a long-term disabling condi-
tion that occurs as a result of DVT3. Endothelial 
cells (EC), forming more than just a wallpaper, 
contribute to maintain normal vascular tone and 
blood fluidity by regulating: (1) systemic blood 
flow, (2) tissue perfusion, (3) recruitment and 
extravasation of pro-inflammatory leukocytes 
through the expression of cell adhesion mole-
cules and the production of cytokines, (4) acti-
vation of platelets and the coagulation cascade 
and (5) the recanalization of obstructive fibrin 
clots that permits reconstitution of blood flow 
and prevents recurrent VT4. Their alteration trig-
gers a chronic inflammation associated with an 
increase in vasoconstrictor and pro-thrombotic 
products leading to ED and then inducing VT5,6. 
In particular, the aberrant generation of reactive 
oxygen species (ROS) has been recently shown to 
reduce the vascular tone, increasing total periph-
eral resistance and promoting hypertension, and 
to induce the endothelial activation that finally 
triggers a local inflammatory and immune re-
sponse responsible for ED6-8. In this context, ROS 
have been shown to damage many components of 
the vascular wall such as the endothelial glycoca-
lyx, whose destruction has been shown to trigger 
ED9-11. The endothelial glycocalyx is a network of 
membrane-bound proteoglycans, glycosamino-
glycan and glycoproteins synthetized by EC that, 
by covering the endothelium luminally, regulates 
nitric oxide-dependent vasorelaxation, controls 
vascular permeability, attenuates leukocyte-ves-
sel wall interactions, modulates the inflamma-
tory and thrombotic state of the vascular wall, 
fulfilling a vasculoprotective role3,7,8,11,12. ROS, by 
acting as degrading factors, modify the glycoca-
lyx proprieties and induce ED, which in turn per-
turbs the ability of EC to produce and maintain a 
functional glycocalyx. Thus, counteracting ROS 
production, pro-inflammatory cytokine synthesis 
and maintaining glycocalyx functions could rep-
resent strategic therapeutic opportunities to treat 
ED-related diseases such as VT, and to prevent 
the related recurrences. Sulodexide (SDX) is a 
natural highly purified mixture of natural gly-
cosaminoglycans, composed by 80% fast-moving 
heparin (6-8000 Dalton) and 20% dermatan sul-
fate, which exhibits antithrombotic and pro-fibri-
nolytic activities and affects normal hemostasis 
to a lesser extent than heparin with a very low 
risk of bleeding13,14. SDX exerts its actions by 
reconstructing the glycocalyx15-17, modulating the 
coagulation cascade13,14,18 and preventing the re-
lease of pro-inflammatory cytokines and metal-
loprotease from white blood cells13,19. Because of 
these properties, SDX is largely used in chron-
ic venous disease (CVD)13,14,17 including patients 
with post-thrombotic syndrome (PTS)17,20, and it 
has recently obtained important clinical evidence 
in the “extension therapy” after initial-standard 
anticoagulant treatment for the secondary pre-
vention of recurrent DVT21-24. In this paper for 
the first time we investigated the ability of SDX 
to prevent ED induced by methylglyoxal (MGO), 
a diabetes-related metabolite, or by ionizing ra-
diation (IR), both shown to promote ED25,26 and 
predispose to VT27,28. In these “in vitro” models 
we showed for the first time that SDX counter-
acted the accumulation of ROS, the production 
of pro-inflammatory cytokines such as tumor ne-
crosis factor-alfa (TNF-α), interleukins 1 (IL-1), 6 
(IL-6) and 8 (IL-8), thereby protecting EC from 
stress-induced DNA damage and apoptosis-me-
diated death.
Materials and Methods 
Cell Culture and Treatments
Human umbilical vein endothelial cells (HU-
VEC) (CloneticsTM, San Diego, CA, USA) were 
cultured as already described26. SDX (0.1 to 5 
mg/L) was provided by Alfasigma S.p.A. (Bo-
logna, Italy), MGO (400 mM)29 and BafA1 (50 
nM)30 by Sigma-Aldrich (Milan, Italy). Radiation 
was delivered as previously described26. The dose 
rate was approximately 1.3 Gy/min and the ap-
plied dose was 4 Gy. The absorbed dose was mea-
sured using a Duplex dosimeter (PTW, Freiburg, 
Germany). Briefly, for the experiments HUVECs 
were seeded in a 96-well microplate at an appro-
priate density of cells/well and then either treated 
with SDX at the concentrations indicated in the 
figures or pretreated with SDX and then treated 
with MGO or IR. Subsequently, the plates were 
incubated at 37°C for the times indicated in the 
figures or figure legends.
Measurement of Cell Viability, Apopto-
sis, Caspase Activity, Superoxide Anion 
Production and Cytokine Secretion 
MTT (ab211091) and TUNEL (ab66108) assays 
from Abcam (Cambridge, MA, USA), were used 
to measure cell viability and apoptosis, respec-
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tively. ROS production was assessed by using 
the Chemiluminescence Superoxide Anion Assay 
Kit (CS1000) from Sigma-Aldrich (Milan, Italy). 
Caspase-Glo®-3/7 (G8090), -8 (G8200) and -9 
(G8211) assay from Promega Corporation (Mad-
ison, WI, USA), were used to measure Caspase 
3, 8 and 9, respectively. The levels of TNF-a, 
IL-1, IL-6 and IL-8 were measured by using 
Quantikine ELISA Kit from R&D Systems Inc. 
(McKinley Place NE, MP, USA). At the end of 
the experiments, the absorbed dose was measured 
using a Duplex dosimeter (PTW, Freiburg, Ger-
many). The optical density value was reported as 
the percentage of variable measured in relation to 
the control group.
Gene Expression Analysis
Real-time reverse transcription polymerase 
chain (RT-PCR) was performed as already de-
scribed31. Total ribonucleic acid (RNA) was pre-
pared using the RNeasy kit (Qiagen, Valencia, 
CA, USA) and reverse transcribed into cDNA 
(complementary deoxyribonucleic acid) by means 
of the iScript cDNA synthesis kit (BioRad, Her-
cules, CA, USA). Quantitative Real-time PCR 
was performed on an ABI 7900HT system using 
SYBR- Green Mastermix (SuperArray, Freder-
ick, MD, USA). PCR products were verified by 
melting curves and were run on a 2% agarose 
gel to confirm the appropriate size. The threshold 
cycle (CT) values for each gene were normalized 
to expression levels of β-actin, as already de-
scribed31. The following primers were used: β-ac-
tin: FW-5’-AGAAAATCTGGCACCACACC-3’, 
RW-5’-AGAGGCGTACAGGGATAGCA-3; IL-
1: FW-5’-CAGGATGAGGACATGAGCAC-3’, 
RW-5’-CTCTGCAGACTCAAACTCCA-3’; IL-
6: FW-5’-TTCGGTACATCCTCGACGGC-3’, 
RW-5’-ACCAGAAGAAGGAATGCCCAT-3’; 
IL-8: FW-5’-TCCTGATTTCTGCAGCTCT-
GTG-3’, RW-5’-GTCCAGCAGAGCTCTCTTC-
CAT-3’; TNFa: FW-5’-TTGACCTCAGCGCT-
GAGTTG-3’, RW-5’-CCTGTAGCCCACGTC-
GTAGC-3’; beclin-1: FW-5’-ACCGTGTCAC-
CATCCAGGAA-3’, RW-5-GAAGCTGTTGG-
CACTTTCTGT-3’. 
Protein Expression Analysis
Immunoblotting was conducted as previously 
described32-35 with the following antibodies: an-
ti-H2A histone family member X (H2AX, clone 
M-20), anti-phospho-H2AX (g-H2AX, clone 
3C10), anti-sequestosome 1 protein (SQSTM1/
p62, clone D3), beclin 1 (BECN1, clone H300) 
and a-tubulin (clone B7) from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Anti-mouse 
or anti-rabbit horseradish peroxidase (HRP)-con-
jugated antibodies (Bethyl Laboratories Inc., 
Montgomery, TX, USA) were used for enhanced 
chemiluminescence (GE Health Life Sciences, 
Piscataway Township, NJ, USA) detection. Sig-
nals from protein bands were digitally acquired 
and quantified using the Chemidoc XRS system 
(Bio-Rad, Hercules, CA, USA). 
Statistical Analysis
Statistical analysis was performed using a one-
way analysis of variance (SPSS software version 
12.0.1; SPSS Inc., Chicago, IL, USA). The results 
were expressed as mean ± standard deviation 
(SD) of triplicate determinations, with p < 0.05 
considered statistically significant.
Results
Sulodexide Protects HUVEC from 
Methylglyoxal- or Irradiation-Induced 
Apoptotic Cell Death by Increasing 
Autophagy
Increasing doses of SDX (in a range between 
0.1 to 5 mg/L) did not affect HUVEC viability 
(Figure 1A) or induce cell death (Figure 1B). 
The maximum concentration of SDX found in 
the plasma of treated patients in a steady state 
condition (1.5 mg/L)13 was used for the follow-
ing experiments. SDX significantly counteracted 
the reduction in cell viability (Figure 2A) and 
increase in apoptosis (Figure 2B) induced by 
MGO or IR. These cytoprotective effects started 
48 hours after SDX pre-treatment and reached 
maximum efficiency in 72-hour pretreated cells 
(Figure 2A and B, SDX+MGO vs. MGO and 
SDX+IR vs. IR). In 72-hour pretreated cells, 
SDX increased cell viability by 41% ± 6 and 
53% ± 8 (Figure 2A) and reduced apoptosis 
by 49% ± 7 and 57% ± 9 (Figure 2B) in MGO 
and IR treated cells, respectively. No statisti-
cally significant differences were described in 
12- or 24-hour SDX pretreated cells (Figure 
2A and 2B). 72 hours of SDX pretreatment 
was used for the following experiments. SDX 
restrained MGO-induced activation of caspase 
8 and caspase 3 by 44.3% ± 8.2 and 43% ± 6, re-
spectively, and IR-induced activation of caspase 
8, caspase 9 and caspase 3 by 32% ± 8, 52% ± 9 
and 39% ± 9, respectively (Figure 2C). SDX up-
regulated Beclin 1 and downregulated p62 basal 
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protein expression (Figure 3A, SDX). MGO and 
IR significantly downregulated Beclin 1 protein 
expression levels while MGO, but not IR, sig-
nificantly increased p62 expression (Figure 3A, 
MGO or IR). MGO and IR treatment counteract-
ed the upregulation of Beclin 1 induced by SDX 
(Figure 3A, SDX+MGO or SDX+IR). Treating 
cells with BafA1 counteracted the cytoprotec-
tive effects of SDX (Figure 3B and 3C). The 
presence of BafA1 reduced the ability of SDX to 
counteract the MGO- or IR-induced reduction 
in cell viability by 42.8% ± 6 (Figure 3B, Ba-
fA1+SDX+MGO vs. SDX+MGO) and 55.2% ± 
7 (Figure 3B, BafA1+SDX+IR vs. SDX+IR) and 
in apoptosis by 71.5% ± 8 (Figure 3B, BafA1+S-
DX+MGO vs. SDX+MGO) and 74.6% ± 11 (Fig-
ure 3B, BafA1+SDX+IR vs. SDX+IR). BafA1 
itself significantly reduced HUVEC viability 
by 28.3% ± 7 (Figure 3B, BafA1 vs. Untreated) 
and increased the percentage of apoptotic cells 
by 18.5% ± 7 (Figure 3A, BafA1 vs. Untreated).
Sulodexide Counteracts Reactive 
Oxygen Species, Pro-Inflammatory 
Cytokine Release and DNA Damage 
Induced by MGO or IR by Involving the 
Autophagy Mechanism
SDX counteracted MGO-induced ROS pro-
duction by 33% ± 6 (Figure 4A, SDX+MGO vs. 
MGO) and IR-induced ROS production by 58% 
± 9 (Figure 4A, SDX+IR vs. IR). These effects 
were significantly nullified by pretreating cells 
with BafA1 (Figure 4A, BafA1+SDX+MGO vs. 
SDX+MGO and BafA1+SDX+IR vs. SDX+IR). 
SDX reduced the neo-synthesis (Figure 4B) and 
release (Figure 4C) of pro-inflammatory cy-
tokines induced by MGO (TNF-α 81% ± 13, 
IL-1 68% ± 11, IL-8 43% ± 12, Figure 4B, SDX-
+MGO vs. MGO) or IR (TNF-α 52% ± 4, IL-1 
37% ± 8, IL-8 52% ± 9, Figure 4B, SDX+IR vs. 
IR). SDX reduced the MGO- or IR-induced re-
lease of TNF-α by 67% ± 12 and 22% ± 4, IL-1 
by 38% ± 9 and 49% ± 3, and IL-8 by 34% ± 5 
and 41% ± 6 (Figure 4B, SDX+MGO vs. MGO 
and SDX+IR vs. IR). Although SDX reduced 
IL-6 gene expression and release induced by IR 
by 38% ± 7 and 59% ± 7, no significant effects 
were described in MGO-treated cells (Figure 
4B and 4C, SDX+MGO vs. MGO and SDX+IR 
vs. IR). BafA1 restrained the effects of SDX, 
restoring the gene expression and release of 
TNF-α, IL-1, IL-6 and IL-8 induced by MGO 
(Figure 4C, BafA1+SDX+MGO vs. SDX+MGO) 
or IR (Figure 4B, BafA1+SDX+IR vs. SDX+IR). 
DNA damage, investigated by assessing the 
phosphorylation of H2AX at Ser 139 (γ-H2AX), 
showed that SDX prevented the accumulation of 
γ-H2AX induced by MGO or IR, effects nulli-
fied by BafA1 treatment (Figure 5).
Discussion
VT is increasingly recognized as an im-
portant cause of morbidity and mortality that 
drastically affects quality of life and productiv-
ity, causing a dramatic increase in healthcare 
costs1,2. Several pathophysiological risk factors 
have been related to VT and among them, ED 
is certainly one of the most important. Endo-
thelium is a complex tissue and each compo-
nent plays a key role in regulating vascular 
homeostasis36 by controlling systemic blood 
Figure 1. Effects of increasing doses of SDX on HUVEC 
viability and apoptosis-mediated cell death. Dose-
dependent effect of SDX on viability (A) and apoptosis (B) 
of HUVEC after 72 hours of treatment. Cell viability was 
measured by MTT and apoptosis by TUNEL assay. Results 
are representative of three independent experiments ±SD.
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flow and tissue perfusion, the movement of flu-
id, ions and other macromolecules, controlling 
the recruitment and extravasation of pro-in-
flammatory leukocytes in response to tissue 
damage and participating in the blood coagula-
tion system4,36. In this context, the glycocalyx, 
a membrane-bound mixture of proteoglycans, 
glycosaminoglycan and glycoproteins that lu-
minally covers endothelium, has been shown 
to actively participate and play a key role in 
EC functions9,10. Thus, loss of the glycocalyx 
has been shown to promote ED, which in turn, 
Figure 2. Effects of SDX in preventing MGO or IR reduction in cell viability and increase in apoptosis. HUVEC were 
pretreated with SDX for 12, 24, 48 or 72 hours and then treated with MGO or IR; cell viability and apoptosis were measured 
72 hours later by MTT or TUNEL assay, respectively. (C) HUVEC treated with SDX for 72 hours and then treated with MGO 
or IR; Caspase 8, 9 and 3 activity were measured 24 hours later. Results are representative of three independent experiments ± 
SD. (*p < 0.05, **p < 0.01 or ***p < 0.001 vs. Untreated, $p < 0.05, $$p < 0.01 or $$$p < 0.001 vs. MGO or IR). 
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by sustaining ROS production, establishes a 
self-sustaining vicious circle that supports and 
amplifies loss of the glycocalyx inducing blood 
cell recruitment and activation of an inflamma-
tory status that finally promotes VT and related 
recurrences3,5-8,37. Thus, restoring the damaged 
glycocalyx represents a therapeutic strategy 
in counteracting VT. SDX is a highly purified 
glycosaminoglycan obtained from porcine di-
gestive mucosa and it is composed of a mixture 
of 80% electrophoretically fast-moving heparin 
fraction with a molecular weight of about 7000 
Da and affinity for antithrombin III, and 20% 
dermatan sulfate, with a molecular weight of 
25,000 Da and affinity for the heparin II cofac-
tor13. Due to its composition, SDX restores the 
vascular endothelial glycocalyx, shows an an-
ti-thrombotic, profibrinolytic and anti-inflam-
matory action3,13-19,38,39 and, for these reasons, it 
is used in the treatment of CVD13,14,17, PTS17,20 
and in the secondary prevention of recurrent 
DVT21-24. Furthermore, other evidence suggests 
that SDX has an anti-oxidant action that coun-
teracts ROS production40,41 and a cell protection 
activity against cellular aging42 and apopto-
sis40,41. However, although the anti-thrombotic, 
Figure 3. Effects of SDX in modulating the basal autophagic activity and its role in mediating SDX cytoprotective effects. 
(A) Cell lysates from HUVEC ± 72 hours of SDX ± MGO or IR were analyzed by immunoblotting with specific antibodies for 
indicated proteins; α-tubulin expression shows the loading of samples. Densitometric analysis of three independent experiments 
is reported below the blots (*p < 0.05, **p < 0.01 or ***p < 0.001 vs. Untreated). (B and C) HUVEC were pretreated with SDX 
for 72 hours in the presence or absence of BafA1 and then treated with MGO or IR; cell viability and apoptosis were measured 
72 hours later by MTT or TUNEL assay, respectively. Results are representative of three independent experiments ±SD. (*p < 
0.05, **p < 0.01 or ***p < 0.001 vs. Untreated, $p < 0.05, $$p < 0.01 or $$$p < 0.001 vs. MGO or IR, £p < 0.05, ££p < 0.01 or £££p 
< 0.001 vs. SDX+MGO or SDX+IR).
SDX counteracts ED stress-induced by activating the autophagic
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Figure 4. Effects of SDX and related induced autophagy in modulating MGO- and IR-mediated production of ROS, TNF-α, 
IL-1, IL-6 and IL-8. HUVEC were pretreated with SDX 72 hours in the presence or absence of BafA1 and then treated with 
MGO or IR; (A) ROS production, (B) TNF-α, IL-1, IL-6 and IL-8 gene expression and (C) release were measured 24 hours 
later. Results are representative of three independent experiments ±SD. (*p < 0.05, **p < 0.01 or ***p < 0.001 vs. Untreated, $p 
< 0.05, $$p < 0.01 or $$$p < 0.001 vs. MGO or IR, ^p < 0.05, ^^p < 0.01 or ^^^p < 0.001 vs. SDX+MGO or SDX+IR, £p < 0.05, ££p < 
0.01 or £££p < 0.001 vs. SDX+MGO or SDX+IR).
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profibrinolytic and anti-inflammatory abilities 
of SDX have been largely investigated, the mo-
lecular mechanisms involved are not completely 
understood nor is the ability of SDX to coun-
teract both metabolic or non-metabolic stresses 
able to induce ED. Herein, we demonstrate for 
the first time that SDX prevented ED induced by 
metabolic and non-metabolic oxidative stresses 
such as MGO or IR, known to potentially pro-
mote VT27,28, by restraining ROS production 
and pro-inflammatory cytokine release through 
activation of the autophagic program. Doses of 
SDX ten times higher than those physiologically 
found at the steady state condition in the blood 
of treated patients (1.5 mg/L)13 did not induce 
any change in cell viability, confirming the ex-
treme pharmacological safety of SDX. Starting 
with this data we have shown that after 2 days 
of daily treatment, SDX prevented stress-in-
duced EC death, suggesting that the drug need-
ed to promote significant changes accounting 
for its cytoprotective action. We found that the 
cytoprotection mediated by SDX depends on its 
ability to prevent stress-induced apoptosis-me-
diated cell death. Apoptosis occurs when cells 
are irreversibly damaged, through the activa-
tion of the extrinsic caspase 8/3- or intrinsic 
caspase 9/3-mediated cascades43,44, known to 
be activated by MGO45 and IR26. We found that 
SDX, already shown to prevent EC apoptosis 
induced by oxygen-glucose deprivation41, also 
significantly counteracts the activation of the 
apoptotic program induced by MGO and IR. 
Thus, our data showed the cytoprotective ef-
fects of SDX indicating that this ability was in-
dependent from the metabolic or non-metabolic 
nature of the stress. Autophagy is a complex 
lysosomal catabolic process by which cells de-
grade or recycle their contents to maintain cel-
lular homeostasis, adapt to stress, and respond 
to disease46,47. In particular, regarding EC, the 
literature indicates the cytoprotective effects of 
autophagy, the loss of which has been shown to 
be a central mechanism in inducing ED47. For 
example, in EC, shear stress-induced increases 
in NO production is markedly blunted in au-
tophagy deficient cells and loss of autophagy 
promotes ROS-mediated ED and inflammatory 
cytokine production46,47. Our experiments re-
vealed that SDX significantly upregulated the 
basal expression of Beclin-1, the main down-
stream effector of the autophagic pathway and 
Figure 5. Effects of SDX and related induced-autophagy in preventing the MGO- or IR-induced DNA damage. Cell lysates 
from HUVEC ± 72 hours of SDX ± BafA1 ± MGO (A) or IR (B) were analyzed by immunoblotting with specific antibodies 
for indicated proteins; α-tubulin expression shows the loading of samples. Densitometric analysis of three independent 
experiments is reported below the blots (*p < 0.05, **p < 0.01 or ***p < 0.001 vs. Untreated, $p < 0.05, $$p < 0.01 or $$$p < 0.001 
vs. MGO or IR, ^p < 0.05, ^^p < 0.01 or ^^^p < 0.001 vs. SDX+MGO or SDX+IR).
SDX counteracts ED stress-induced by activating the autophagic
2677
downregulated the expression of p62, the main 
inhibitor48,49. Thus, we supposed that the acti-
vation of the autophagic program by SDX has 
a cytoprotective function. Our hypothesis was 
demonstrated by using the autophagy inhibitor 
BafA1. BafA1 nullified the anti-oxidant and 
cytoprotective proprieties of SDX, confirming 
the hypothesis that increasing the intracellular 
endothelial autophagic flux could be one of the 
molecular mechanisms by which SDX protects 
EC and prevents ED. These data are consistent 
with recent studies that showed cardiovascu-
lar benefit from the upregulation of autophagy 
by some molecules47,50,51. When cells die they 
trigger an inflammatory response that partici-
pates in tissue repair but can also cause tissue 
damage; thus, inflammation contributes to the 
pathogenesis of a number of diseases52. Unlike 
healthy endothelium, ED promotes the release 
of significant amounts of cytokines that, by 
promoting and sustaining local chronic/system-
ic inflammation, finally increase the surface 
of ED and could predispose to VT3,6. SDX has 
been already shown to counteract inflammation 
in patients with chronic venous insufficiency 
by directly reducing the release of pro-inflam-
matory cytokines from EC39,42. However, our 
researches show for the first time in a ED cell 
model induced by metabolic and non-metabolic 
oxidative stresses, known to promote VT, that 
SDX: i) counteracted TNF-α, IL-1 and IL-
8 neosynthesis and release induced by MGO 
or IR; ii) counteracted IL-6 neosynthesis and 
release induced by IR but not by MGO; iii) 
negatively modulated pro-inflammatory cyto-
kine neosynthesis and release by activating the 
autophagic program. In particular, considering 
that TNF-α, IL-6 and IL-8 have been associat-
ed with an increased risk of DVT recurrence53, 
our data support the possible role of SDX in the 
secondary prevention of recurrent DVT. Fur-
thermore, the fact that SDX reduced the cyto-
kine mRNA levels corroborate the previous hy-
pothesis that this drug could induce significant 
intracellular changes, such as gene expression54. 
Moreover, the fact that in this “in vitro” model 
the anti-inflammatory action of SDX was found 
to be strictly correlated with authophagy con-
firms the key role of this program in mediating 
the cytoprotective effects of SDX. MGO and 
IR, directly or by inducing inflammation finally 
lead to cell death by causing DNA damage55-57. 
No data have been yet collected on the ability 
of SDX to protect the DNA from stress-induced 
damage and we found that SDX prevented phos-
phorylation of H2AX, known to be a specific 
marker for DNA damage58. 
Conclusions
Although these data have been collected “in 
vitro”, they clearly show the ability of SDX to 
protect EC from apoptosis and prevent ROS-me-
diated ED, counteracting both metabolic and 
non-metabolic toxic stresses potentially associat-
ed with an increased risk of VT. SDX seems to be 
able to block the vicious circle triggered by ROS 
and responsible for the chronic inflammation in 
venous disease. Our study increases the knowl-
edge of the mechanisms of action of SDX against 
ED and supports the use of SDX in the treatment 
of CVD, PTS and in the secondary prevention of 
recurrent DVT.
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